Janus Henderson Group PLC Buys 290,153 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Janus Henderson Group PLC lifted its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 27.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,331,877 shares of the company's stock after acquiring an additional 290,153 shares during the period. Janus Henderson Group PLC owned about 2.73% of Enliven Therapeutics worth $30,001,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. FMR LLC increased its position in shares of Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after acquiring an additional 199,692 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after acquiring an additional 55,283 shares in the last quarter. Pictet Asset Management Holding SA increased its position in shares of Enliven Therapeutics by 16.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after acquiring an additional 135,969 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Enliven Therapeutics by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 762,718 shares of the company's stock worth $17,165,000 after acquiring an additional 12,510 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new position in shares of Enliven Therapeutics in the fourth quarter worth approximately $15,106,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Up 0.4%

ELVN stock traded up $0.07 during trading hours on Tuesday, hitting $16.92. The company's stock had a trading volume of 45,898 shares, compared to its average volume of 263,177. The company has a market capitalization of $830.10 million, a PE ratio of -8.93 and a beta of 1.07. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The stock has a 50 day moving average price of $18.76 and a two-hundred day moving average price of $21.58.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $18.39, for a total transaction of $122,606.13. Following the completion of the transaction, the chief operating officer now owns 309,976 shares of the company's stock, valued at approximately $5,700,458.64. The trade was a 2.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the completion of the sale, the insider now directly owns 997,688 shares of the company's stock, valued at $16,032,846.16. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 76,111 shares of company stock valued at $1,493,145 over the last ninety days. Corporate insiders own 29.20% of the company's stock.

Analysts Set New Price Targets

ELVN has been the topic of several analyst reports. HC Wainwright lifted their target price on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Jones Trading lowered their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $37.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.